Narrow Therapeutic Window of Ribavirin as an Inhibitor of Nitric Oxide Synthesis is Broadened by Macromolecular Prodrugs
Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerab...
Saved in:
Published in | Biomacromolecules Vol. 14; no. 11; pp. 3916 - 3926 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
American Chemical Society
11.11.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent. |
---|---|
AbstractList | Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC sub(50) and IC sub(50) being 7 and 19 mu M, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 mu M (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent. Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent. Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC₅₀ and IC₅₀ being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent. Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent.Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success, the mechanism of action of this drug against HCV remains a subject of debate. Furthermore, the appeal of this therapeutic agent is considerably lessened by unfavorable pharmacokinetics. This interdisciplinary study contributes to the understanding of intracellular effects exerted by RBV and presents a successful design of macromolecular prodrugs of RBV to achieve a safer treatment. Specifically, we demonstrate that RBV exhibits a pronounced anti-inflammatory activity in cultured macrophages as is evidenced by a 2-fold decrease in the levels of produced nitric oxide achieved using a clinically relevant concentration of this drug. However, this effect was characterized by a rather narrow therapeutic window with experimental values of EC50 and IC50 being 7 and 19 μM, respectively. Macromolecular prodrugs were obtained using an acrylate derivative of RBV, RAFT polymerization technique, and N-vinyl pyrrolidone as a partner monomer. The synthesized polymers were characterized with uniform molecular weights, relatively narrow polydispersities, and gradually increasing content of RBV. The resulting polymer therapeutics were effective in delivering their payload to the cultured macrophages and afforded a significantly wider therapeutic window, as much as >1000 μM (18-fold in relative values). Taken together, this work contributes significantly to the development of safer methods for delivery of RBV, as well as understanding the mechanism of action and origins of the side effects of this broad-spectrum antiviral agent. |
Author | Kryger, Mille B. L Smith, Anton A. A Wohl, Benjamin M Zelikin, Alexander N |
AuthorAffiliation | Department of Chemistry Aarhus University iNano Interdisciplinary Nanoscience Centre |
AuthorAffiliation_xml | – name: Department of Chemistry – name: iNano Interdisciplinary Nanoscience Centre – name: Aarhus University |
Author_xml | – sequence: 1 givenname: Benjamin M surname: Wohl fullname: Wohl, Benjamin M – sequence: 2 givenname: Anton A. A surname: Smith fullname: Smith, Anton A. A – sequence: 3 givenname: Mille B. L surname: Kryger fullname: Kryger, Mille B. L – sequence: 4 givenname: Alexander N surname: Zelikin fullname: Zelikin, Alexander N email: zelikin@chem.au.dk |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27948520$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24156371$$D View this record in MEDLINE/PubMed |
BookMark | eNqN0ltrFTEQAOAgLfaiD_4ByYugD9smu5PdzaMWL4XailZ8XGaTWU_KbnJMdrXn35vaUwUpKAQSki_DMDMHbMcHT4w9keJIilIe9xMIKaBND9i-VGVdQC3KnV9nVTSNbvbYQUpXQghdgXrI9kqQqq4auc-uzzHG8INfrijimpbZGf7FeZuvwsA_uh6_u-g8x8TR81O_cr2bQ7x5PHdzzPri2lninzZ-XlFyief1Kga05MnyfsPfo4lhCiOZZcTIP8Rg4_I1PWK7A46JHm_3Q_b5zevLk3fF2cXb05OXZwWClHNhtTW210pqIVuDSg2qlY1VtkJb9TQgtrIlodp2AE01gCQCXdelsgL0ANUhe34bdx3Dt4XS3E0uGRpH9BSW1JW5Kgqqstb_pLmcAELV8B8UVM63qqHN9OmWLv1EtltHN2HcdHc9yODZFmAyOA4RvXHpj2s0tKoU2R3fulzPlCINnXEzzi74OaIbOym6m2nofk9D_vHirx93Qe-z2yzQpO4qLNHnrtzjfgK557-H |
CitedBy_id | crossref_primary_10_1038_s41598_020_66944_4 crossref_primary_10_1371_journal_pntd_0010289 crossref_primary_10_1016_j_tetasy_2017_05_003 crossref_primary_10_1039_C4PY00624K crossref_primary_10_1016_j_mtadv_2021_100140 crossref_primary_10_1002_adhm_201300637 crossref_primary_10_1002_adhm_201400307 crossref_primary_10_1002_adfm_201304312 crossref_primary_10_1080_15257770_2020_1723624 crossref_primary_10_3390_ph17050644 crossref_primary_10_1039_C5SC03257A crossref_primary_10_3390_molecules22101736 crossref_primary_10_1016_j_jconrel_2015_04_016 crossref_primary_10_1016_j_tips_2015_05_001 crossref_primary_10_1039_C4SC02754J crossref_primary_10_1155_2015_923614 crossref_primary_10_1016_j_jconrel_2014_09_032 crossref_primary_10_3390_molecules27072337 crossref_primary_10_1021_acs_molpharmaceut_6b00826 crossref_primary_10_1039_C5CC08011H crossref_primary_10_1039_C4DT03609C crossref_primary_10_1016_j_apmt_2020_100887 crossref_primary_10_3390_polym14040701 |
Cites_doi | 10.1002/cmdc.201000352 10.1002/hep.21072 10.1016/S0006-2952(97)00223-2 10.1021/bm901129x 10.1177/109158189801700408 10.1021/cr9001403 10.1016/j.jconrel.2011.03.028 10.1038/nrd2468 10.1002/hep.1840360730 10.1016/j.ijbiomac.2012.02.019 10.3851/IMP1609 10.1093/clinids/12.6.1139 10.1016/j.dld.2010.10.007 10.1128/AAC.30.2.201 10.1208/s12249-008-9122-0 10.1021/nn204319b 10.1097/COH.0b013e32834b87f8 10.1053/he.2000.5789 10.1039/c3cc00315a 10.1016/j.ejphar.2005.11.037 10.1038/nrd703 10.1039/b904456f 10.3945/jn.108.100495 10.1016/j.polymer.2008.09.006 10.1007/s13277-010-0019-7 10.1002/mabi.200800163 10.1055/s-2006-947298 10.1016/S0021-9258(18)31375-9 10.1111/j.1478-3231.2008.01896.x 10.1038/nrd937 10.1021/nn700063w 10.1016/S1476-5586(03)80011-8 10.1016/0041-008X(84)90138-8 10.1016/S0169-409X(99)00024-1 10.1002/mabi.201300244 10.1517/14656560903580001 10.1002/pola.22606 10.1096/fj.06-6779com 10.1002/app.27680 10.1021/bc040241m 10.1038/nature04082 10.1295/polymj.30.31 10.1016/S0973-6883(12)60090-5 10.1021/bm700498j 10.1073/pnas.70.4.1174 10.1016/S0031-6997(25)06663-3 10.1016/j.colsurfb.2009.05.023 10.3109/10717544.2010.536272 10.1038/sj.cdd.4401115 10.1038/nrd1088 10.1016/j.biomaterials.2003.10.003 10.1016/S0039-9140(01)00323-X 10.1191/0961203305LU2109OA 10.1159/000050085 10.1002/pola.23479 10.1126/science.177.4050.705 10.1055/s-2004-832928 10.1021/jm010969d |
ContentType | Journal Article |
Copyright | Copyright © 2013 American
Chemical Society 2015 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2013 American Chemical Society – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7QO 8FD FR3 P64 7S9 L.6 |
DOI | 10.1021/bm401048s |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | Engineering Research Database MEDLINE AGRICOLA MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Applied Sciences |
EISSN | 1526-4602 |
EndPage | 3926 |
ExternalDocumentID | 24156371 27948520 10_1021_bm401048s b336804221 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 02 23N 4.4 53G 55A 5GY 7~N AABXI ABFLS ABMVS ABPTK ABUCX ACGFS ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED ED~ EJD F5P GNL IH9 JG JG~ LG6 P2P RNS ROL RSW TN5 UI2 VF5 VG9 W1F X XKZ --- -~X 5VS AAHBH AAYXX ABBLG ABJNI ABLBI ABQRX ADHLV AHGAQ BAANH CITATION CUPRZ GGK ZCA ~02 AFFNX IHE IQODW CGR CUY CVF ECM EIF NPM 7X8 7QO 8FD FR3 P64 7S9 L.6 |
ID | FETCH-LOGICAL-a411t-d9dcdb9519018ca55f5817d5d3ad3befaa818e0588f49e6441ee496625d049f43 |
IEDL.DBID | ACS |
ISSN | 1525-7797 1526-4602 |
IngestDate | Thu Jul 10 22:43:06 EDT 2025 Fri Jul 11 15:35:53 EDT 2025 Fri Jul 11 07:28:35 EDT 2025 Mon Jul 21 05:55:41 EDT 2025 Wed Apr 02 07:25:25 EDT 2025 Thu Apr 24 23:08:12 EDT 2025 Sun Jul 06 05:03:54 EDT 2025 Thu Aug 27 13:42:22 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Biological properties Triazole derivative copolymer Control release polymer Antiinflammatory agent Red blood cell Cytotoxicity Drug carrier Prodrug Experimental study Biological activity Ribavirin Monodispersed polymer Chain transfer Hepatocyte Activity concentration relation Nitric oxide Preparation Pyrrolidone(vinyl) copolymer Antiviral Acrylate copolymer Radical copolymerization |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a411t-d9dcdb9519018ca55f5817d5d3ad3befaa818e0588f49e6441ee496625d049f43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 24156371 |
PQID | 1450183648 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2000543269 proquest_miscellaneous_1524405649 proquest_miscellaneous_1450183648 pubmed_primary_24156371 pascalfrancis_primary_27948520 crossref_citationtrail_10_1021_bm401048s crossref_primary_10_1021_bm401048s acs_journals_10_1021_bm401048s |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 XKZ 7~N VG9 W1F ACS AEESW AFEFF ABMVS ABUCX IH9 AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 2013-11-11 |
PublicationDateYYYYMMDD | 2013-11-11 |
PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-11 day: 11 |
PublicationDecade | 2010 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States |
PublicationTitle | Biomacromolecules |
PublicationTitleAlternate | Biomacromolecules |
PublicationYear | 2013 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | Sharma P. (ref3/cit3) 2006; 26 De Clercq E. (ref19/cit19) 2002; 1 Moorcroft M. J. (ref48/cit48) 2001; 54 Nair B. (ref43/cit43) 1998; 17 Levy G. A. (ref38/cit38) 2006; 43 Oberoi H. S. (ref62/cit62) 2011; 153 Jain M. K. (ref11/cit11) 2010; 11 Lavignac N. (ref59/cit59) 2009; 9 Li X. (ref35/cit35) 2008; 49 Kanuri G. (ref49/cit49) 2009; 139 Gilbert B. E. (ref15/cit15) 1986; 30 Streeter D. G. (ref22/cit22) 1973; 70 Boyer C. (ref45/cit45) 2009; 109 Nielsen A. L. (ref54/cit54) 2009; 73 ref2/cit2 Brochot E. (ref14/cit14) 2010; 15 Li X. (ref34/cit34) 2008; 108 Neeraj A. (ref36/cit36) 2011; 18 Di Stefano G. (ref41/cit41) 1997; 29 Wannachaiyasit S. (ref30/cit30) 2008; 9 Marletta M. A. (ref21/cit21) 1993; 268 Tsubota A. (ref51/cit51) 2002; 45 Rautio J. (ref53/cit53) 2008; 7 Zelikin A. N. (ref47/cit47) 2007; 8 ref42/cit42 Chang C.-W. (ref58/cit58) 2009; 24 Moncada S. (ref1/cit1) 1991; 43 Feld J. J. (ref17/cit17) 2005; 436 De Franceschi L. (ref12/cit12) 2000; 31 Shimoni O. (ref46/cit46) 2012; 6 Patterson J. L. (ref10/cit10) 1990; 12 Kast R. E. (ref23/cit23) 2003; 5 Allison A. C. (ref25/cit25) 2005; 14 Kryger M. B. L. (ref26/cit26) 2013; 49 Kovar L. (ref60/cit60) 2010; 31 Veronese F. M. (ref61/cit61) 2005; 16 Pissuwan D. (ref57/cit57) 2010; 11 Fried M. W. (ref7/cit7) 2002; 36 Michaelis M. (ref20/cit20) 2007; 21 Sidwell R. W. (ref9/cit9) 1972; 177 Vlieghe P. (ref37/cit37) 2002; 45 Fried M. W. (ref6/cit6) 2004; 24 Duncan R. (ref27/cit27) 2003; 2 Zelikin A. N. (ref56/cit56) 2007; 1 Di Stefano G. (ref40/cit40) 1997; 54 Majano P. L. (ref24/cit24) 2003; 10 Li X. (ref39/cit39) 2008; 46 Brillanti S. (ref8/cit8) 2011; 43 Kmoníčková E. (ref52/cit52) 2006; 530 Canonico P. G. (ref13/cit13) 1984; 74 Naik G. S. (ref16/cit16) 2012; 2 Gao Y. (ref33/cit33) 1998; 30 Tan S.-L. (ref5/cit5) 2002; 1 Giammona G. (ref32/cit32) 1999; 39 Li W. J. (ref29/cit29) 2012; 50 Dore G. J. (ref4/cit4) 2011; 6 Wan L. (ref31/cit31) 2006; 3 Li W. (ref28/cit28) 2010; 5 Kaneda Y. (ref44/cit44) 2004; 25 Hofmann W. P. (ref18/cit18) 2008; 28 Ren S. D. (ref55/cit55) 2009; 47 Markusic D. M. (ref50/cit50) 2009 |
References_xml | – volume: 29 start-page: 420 issue: 5 year: 1997 ident: ref41/cit41 publication-title: Italian J. Gastroenterol. Hepatol. – volume: 5 start-page: 1893 issue: 11 year: 2010 ident: ref28/cit28 publication-title: ChemMedChem doi: 10.1002/cmdc.201000352 – volume: 43 start-page: 581 issue: 3 year: 2006 ident: ref38/cit38 publication-title: Hepatology doi: 10.1002/hep.21072 – volume: 54 start-page: 357 issue: 3 year: 1997 ident: ref40/cit40 publication-title: Biochem. Pharmacol. doi: 10.1016/S0006-2952(97)00223-2 – volume: 11 start-page: 412 issue: 2 year: 2010 ident: ref57/cit57 publication-title: Biomacromolecules doi: 10.1021/bm901129x – volume: 17 start-page: 95 issue: 4 year: 1998 ident: ref43/cit43 publication-title: Int. J. Toxicol. doi: 10.1177/109158189801700408 – volume: 109 start-page: 5402 issue: 11 year: 2009 ident: ref45/cit45 publication-title: Chem. Rev. doi: 10.1021/cr9001403 – volume: 153 start-page: 64 issue: 1 year: 2011 ident: ref62/cit62 publication-title: J. Controlled Release doi: 10.1016/j.jconrel.2011.03.028 – volume: 7 start-page: 255 issue: 3 year: 2008 ident: ref53/cit53 publication-title: Nat. Rev. Drug Discovery doi: 10.1038/nrd2468 – volume: 36 start-page: s237 issue: 5 year: 2002 ident: ref7/cit7 publication-title: Hepatology doi: 10.1002/hep.1840360730 – volume: 50 start-page: 974 issue: 4 year: 2012 ident: ref29/cit29 publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2012.02.019 – volume: 15 start-page: 687 issue: 5 year: 2010 ident: ref14/cit14 publication-title: Antiviral Ther. doi: 10.3851/IMP1609 – volume: 12 start-page: 1139 issue: 6 year: 1990 ident: ref10/cit10 publication-title: Rev. Infect. Dis. doi: 10.1093/clinids/12.6.1139 – volume: 43 start-page: 425 year: 2011 ident: ref8/cit8 publication-title: Digest. Liver Dis. doi: 10.1016/j.dld.2010.10.007 – volume: 30 start-page: 201 issue: 2 year: 1986 ident: ref15/cit15 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.30.2.201 – volume: 9 start-page: 840 issue: 3 year: 2008 ident: ref30/cit30 publication-title: AAPS PharmSciTech doi: 10.1208/s12249-008-9122-0 – volume: 6 start-page: 1463 issue: 2 year: 2012 ident: ref46/cit46 publication-title: ACS Nano doi: 10.1021/nn204319b – volume: 6 start-page: 508 year: 2011 ident: ref4/cit4 publication-title: Curr. Opin. HIV AIDS doi: 10.1097/COH.0b013e32834b87f8 – volume: 31 start-page: 997 issue: 4 year: 2000 ident: ref12/cit12 publication-title: Hepatology doi: 10.1053/he.2000.5789 – volume: 49 start-page: 2643 issue: 26 year: 2013 ident: ref26/cit26 publication-title: Chem. Commun. doi: 10.1039/c3cc00315a – volume: 530 start-page: 179 issue: 1 year: 2006 ident: ref52/cit52 publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2005.11.037 – volume: 1 start-page: 13 year: 2002 ident: ref19/cit19 publication-title: Nat. Rev. Drug Discovery doi: 10.1038/nrd703 – volume: 24 start-page: 3580 year: 2009 ident: ref58/cit58 publication-title: Chem. Commun. doi: 10.1039/b904456f – volume: 139 start-page: 482 issue: 3 year: 2009 ident: ref49/cit49 publication-title: J. Nutr. doi: 10.3945/jn.108.100495 – volume: 49 start-page: 4769 issue: 22 year: 2008 ident: ref35/cit35 publication-title: Polymer doi: 10.1016/j.polymer.2008.09.006 – volume: 31 start-page: 233 issue: 4 year: 2010 ident: ref60/cit60 publication-title: Tumor Biol. doi: 10.1007/s13277-010-0019-7 – volume: 9 start-page: 480 issue: 5 year: 2009 ident: ref59/cit59 publication-title: Macromol. Biosci. doi: 10.1002/mabi.200800163 – volume: 26 start-page: 285 issue: 3 year: 2006 ident: ref3/cit3 publication-title: Semin. Liver Dis. doi: 10.1055/s-2006-947298 – volume: 268 start-page: 12231 year: 1993 ident: ref21/cit21 publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)31375-9 – volume: 28 start-page: 1332 year: 2008 ident: ref18/cit18 publication-title: Liver Int. doi: 10.1111/j.1478-3231.2008.01896.x – volume: 1 start-page: 867 year: 2002 ident: ref5/cit5 publication-title: Nat. Rev. Drug Discovery doi: 10.1038/nrd937 – volume: 1 start-page: 63 issue: 1 year: 2007 ident: ref56/cit56 publication-title: ACS Nano doi: 10.1021/nn700063w – volume: 5 start-page: 3 year: 2003 ident: ref23/cit23 publication-title: Neoplasia doi: 10.1016/S1476-5586(03)80011-8 – ident: ref2/cit2 – volume: 74 start-page: 155 issue: 2 year: 1984 ident: ref13/cit13 publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/0041-008X(84)90138-8 – volume: 39 start-page: 153 issue: 1 year: 1999 ident: ref32/cit32 publication-title: Adv. Drug Delivery Rev. doi: 10.1016/S0169-409X(99)00024-1 – ident: ref42/cit42 doi: 10.1002/mabi.201300244 – volume: 11 start-page: 673 year: 2010 ident: ref11/cit11 publication-title: Expert Opin. Pharmacother. doi: 10.1517/14656560903580001 – volume: 46 start-page: 2734 issue: 8 year: 2008 ident: ref39/cit39 publication-title: J. Polym. Sci., Polym. Chem. doi: 10.1002/pola.22606 – volume: 21 start-page: 81 year: 2007 ident: ref20/cit20 publication-title: FASEB J. doi: 10.1096/fj.06-6779com – volume: 108 start-page: 431 issue: 1 year: 2008 ident: ref34/cit34 publication-title: J. Appl. Polym. Sci. doi: 10.1002/app.27680 – volume: 16 start-page: 775 issue: 4 year: 2005 ident: ref61/cit61 publication-title: Bioconjugate Chem. doi: 10.1021/bc040241m – volume: 436 start-page: 967 year: 2005 ident: ref17/cit17 publication-title: Nature doi: 10.1038/nature04082 – volume: 3 issue: 1 year: 2006 ident: ref31/cit31 publication-title: AIDS Res. Ther. – volume: 30 start-page: 31 issue: 1 year: 1998 ident: ref33/cit33 publication-title: Polym. J. doi: 10.1295/polymj.30.31 – volume: 2 start-page: 42 issue: 1 year: 2012 ident: ref16/cit16 publication-title: J. Clin. Exp. Hepatol. doi: 10.1016/S0973-6883(12)60090-5 – volume: 8 start-page: 2950 issue: 9 year: 2007 ident: ref47/cit47 publication-title: Biomacromolecules doi: 10.1021/bm700498j – volume: 70 start-page: 1174 issue: 4 year: 1973 ident: ref22/cit22 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.70.4.1174 – volume: 43 start-page: 109 issue: 2 year: 1991 ident: ref1/cit1 publication-title: Pharmacol. Rev. doi: 10.1016/S0031-6997(25)06663-3 – volume: 73 start-page: 267 issue: 2 year: 2009 ident: ref54/cit54 publication-title: Colloids Surf., B doi: 10.1016/j.colsurfb.2009.05.023 – volume: 18 start-page: 272 issue: 4 year: 2011 ident: ref36/cit36 publication-title: Drug Delivery doi: 10.3109/10717544.2010.536272 – volume: 10 start-page: S13 year: 2003 ident: ref24/cit24 publication-title: Cell Death Differ. doi: 10.1038/sj.cdd.4401115 – volume: 2 start-page: 347 issue: 5 year: 2003 ident: ref27/cit27 publication-title: Nat. Rev. Drug Discovery doi: 10.1038/nrd1088 – volume: 25 start-page: 3259 issue: 16 year: 2004 ident: ref44/cit44 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2003.10.003 – start-page: 9 year: 2009 ident: ref50/cit50 publication-title: BMC Biotechnol. – volume: 54 start-page: 785 year: 2001 ident: ref48/cit48 publication-title: Talanta doi: 10.1016/S0039-9140(01)00323-X – volume: 14 start-page: s2 year: 2005 ident: ref25/cit25 publication-title: Lupus doi: 10.1191/0961203305LU2109OA – volume: 45 start-page: 33 year: 2002 ident: ref51/cit51 publication-title: Intervirology doi: 10.1159/000050085 – volume: 47 start-page: 4267 issue: 17 year: 2009 ident: ref55/cit55 publication-title: J. Polym. Sci., Polym. Chem. doi: 10.1002/pola.23479 – volume: 177 start-page: 705 issue: 4050 year: 1972 ident: ref9/cit9 publication-title: Science doi: 10.1126/science.177.4050.705 – volume: 24 start-page: 47 issue: 2 year: 2004 ident: ref6/cit6 publication-title: Semin. Liver Dis. doi: 10.1055/s-2004-832928 – volume: 45 start-page: 1275 issue: 6 year: 2002 ident: ref37/cit37 publication-title: J. Med. Chem. doi: 10.1021/jm010969d |
SSID | ssj0009345 |
Score | 2.225066 |
Snippet | Ribavirin (RBV), a broad-spectrum antiviral agent, is a standard medication against hepatitis C virus (HCV). However, despite the decades of clinical success,... |
SourceID | proquest pubmed pascalfrancis crossref acs |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3916 |
SubjectTerms | adverse effects Animals anti-inflammatory activity Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - chemical synthesis Antiviral Agents - chemistry Antiviral Agents - pharmacology Applied sciences Biological and medical sciences Cell Survival - drug effects Cells, Cultured Dose-Response Relationship, Drug Drug Design drug therapy drugs Exact sciences and technology Hep G2 Cells Hepatitis C virus Humans inhibitory concentration 50 Macromolecular Substances - chemical synthesis Macromolecular Substances - chemistry Macromolecular Substances - pharmacology macrophages Macrophages - drug effects Macrophages - metabolism mechanism of action median effective concentration Medical sciences Mice Molecular Structure molecular weight nitric oxide Nitric Oxide - biosynthesis Organic polymers pharmacokinetics Pharmacology. Drug treatments Physicochemistry of polymers polymerization polymers Polymers with particular properties Preparation, kinetics, thermodynamics, mechanism and catalysts Prodrugs - chemical synthesis Prodrugs - chemistry Prodrugs - pharmacology pyrrolidones Ribavirin - chemistry Ribavirin - pharmacology Structure-Activity Relationship Time Factors |
Title | Narrow Therapeutic Window of Ribavirin as an Inhibitor of Nitric Oxide Synthesis is Broadened by Macromolecular Prodrugs |
URI | http://dx.doi.org/10.1021/bm401048s https://www.ncbi.nlm.nih.gov/pubmed/24156371 https://www.proquest.com/docview/1450183648 https://www.proquest.com/docview/1524405649 https://www.proquest.com/docview/2000543269 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT9wwELYoPbQSKn3CtrByH4deQuNX4hzRFgSV2FYFVG6RHdsQAVm02a2gv75jJ9ktgqVSTskkcuyx5xuN_X0IfdKKpNYXWbk1LOLUpZGKnYjiWGkiE2tpUJ47GCZ7x_zbiThZQh8XVPAp-aIvuc8ZZP0IPaaJTH2GtT04nDPrsqBE7HV8ACpmaUcf9O-rPvQU9a3Qs3KlaugF18hXLMaXIc7srqKv3WmdZnvJ-dZ0oreKP3fJGx_6hefoWYsz8XbjGC_Qkq1eoieDTt7tFboeBvpFfDQ_gIV_QYIOt0YO_yy1-l2OywqrGqsK71dnpYbJP_YPh6Wn9cffr0tj8eFNBRiyLmsMFyT1ChYya7C-wQcq7PVr5XfxD1iqx9PT-jU63t05GuxFrQxDpDghk8hkpjAakBhAB1koIZyQJDXCMGWYtk4pCPo2FlI6nlmPr6zlkEVRYSD9cJy9QcvVqLLrCMtE0kzQAjCX4sxmAWLCh5VxLJZa9lAfxilvp1Gdhwo5JfmsA3voczeEedGSmHstjYv7TD_MTK8a5o77jPq3_GBmSVNPm0PjHnrfOUYOA-SrKaqyoym0jXsuRJZw-YCNAPQEEJNni21ogM2AosFmrfG8eSt8es1S8vZ__fIOPaVep8PvTyQbaHkyntpNQEsT3Q-z5S_Odg2c |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLVgPAxpYnxTNopBPPCSLf5qnMep2tTBWhDrxN4iO7YhGqRT3aKNX8-1k7YMbYCUp-Qmcq6v7XN17XMQeqMVyWwosnJrWMKpyxKVOpGkqdJE9qylUXluOOoNTvi7U3Ha0uSEszDQCA9f8rGIv2IXILv6Ow-pg_S30R0AITQkWnv94xXBLouCxEHOBxBjni1YhH5_NaxApb-yAm2cKw_OcI2Kxc0wMy43B5uNblFsaNxlcrYzn-md8ucfHI7_9yf30b0WdeK9JkweoFu2fojW-wuxt0foYhTJGPF4dRwLf4Z0HW5NHP5UafWjmlY1Vh6rGh_WXysNU8E0PBxVgeQff7iojMXHlzUgSl95DBek-AqmNWuwvsRDFXf-tWK8-CNM3NP5F_8YnRzsj_uDpBVlSBQnZJaY3JRGAy4DICFLJYQTkmRGGKYM09YpBRDApkJKx3Mb0Ja1HHIqKgwkI46zJ2itntT2GcKyJ2kuaAkITHFm8wg44cPKOJZKLTuoC_4r2kHli1gvp6RYOrCD3i56sihbSvOgrPHtOtPXS9PzhsfjOqPulXBYWtIskOjQtINeLeKjgA4KtRVV28kc2sYDMyLrcfkXGwFYCgAnz2-2oRFEA6YGm6dNAK5aEZJtlpHn__LLS7Q-GA-PiqPD0fstdJcGBY-wc5Fso7XZdG5fAI6a6W4cQL8AZfgV_Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELZgSDAJ8XNA-VEM4oGXjNixG-dxKlQbsG5im9hbZMf2iIC0qlu08ddz56YtQxsg5Sm5RBf7bH-ns7-PkFdGs9xhkVU4myWC-zzRqZdJmmrDVM85HpXndoe97SPx_lget4kinoUBJwJ8KcQiPo7qsfUtwwB7Y74LTB9UuEquYbkOk62t_sGKZDeLosQo6QOoscgXTEK_v4qrUBXOrUI3xzpAg_i5ksXlUDMuOYPbZG_pbNxp8nVzNjWb1c8_eBz__2_ukFst-qRb83C5S6645h650V-Ivt0np8NIykgPV8ey6GdI2-HWyNNPtdE_6kndUB2obuhO86U2MCVM8OGwRrJ_undaW0cPzhpAlqEOFC5I9TVMb85Sc0Z3ddwB2Iry0n2YwCezk7BBjgbvDvvbSSvOkGjB2DSxha2sAXwGgEJVWkovFcuttJm2mXFea4ACLpVKeVE4RF3OCcituLSQlHiRPSBrzahxjwhVPcULyStAYlpkrojAEz6src9SZVSHdKENy3ZwhTLWzTkrlw3YIa8XvVlWLbU5Kmx8u8j05dJ0POfzuMioey4klpY8RzIdnnbIi0WMlNBBWGPRjRvNwDeBDIlZT6i_2EjAVAA8RXG5DY9gGrA12DycB-HKC0y6s5w9_le7PCfX998Oyo87ww9PyDpHIQ_cwMiekrXpZOaeAZyamm4cQ78AaNUYgA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Narrow+Therapeutic+Window+of+Ribavirin+as+an+Inhibitor+of+Nitric+Oxide+Synthesis+is+Broadened+by+Macromolecular+Prodrugs&rft.jtitle=Biomacromolecules&rft.au=Wohl%2C+Benjamin+M&rft.au=Smith%2C+Anton+A.+A&rft.au=Kryger%2C+Mille+B.+L&rft.au=Zelikin%2C+Alexander+N&rft.date=2013-11-11&rft.pub=American+Chemical+Society&rft.issn=1525-7797&rft.eissn=1526-4602&rft.volume=14&rft.issue=11&rft.spage=3916&rft.epage=3926&rft_id=info:doi/10.1021%2Fbm401048s&rft.externalDocID=b336804221 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-7797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-7797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-7797&client=summon |